guest ::
| Home > Publications Database > Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. > print |
| Home > Publications Database > Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. > print |
| 001 | 139314 | ||
| 005 | 20240321220609.0 | ||
| 024 | 7 | _ | |a 10.1002/mds.26973 |2 doi |
| 024 | 7 | _ | |a pmid:28436538 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC5808453 |2 pmc |
| 024 | 7 | _ | |a 0885-3185 |2 ISSN |
| 024 | 7 | _ | |a 1531-8257 |2 ISSN |
| 024 | 7 | _ | |a altmetric:21127371 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-05636 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Höglinger, Günter U |0 P:(DE-2719)2811373 |b 0 |e First author |
| 245 | _ | _ | |a Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. |
| 260 | _ | _ | |a New York, NY |c 2017 |b Wiley |
| 264 | _ | 1 | |3 online |2 Crossref |b Wiley |c 2017-04-24 |
| 264 | _ | 1 | |3 print |2 Crossref |b Wiley |c 2017-06-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1589983765_10856 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Two recent, randomized, placebo-controlled phase II/III trials (clinicaltrials.gov: NCT01110720, NCT01049399) of davunetide and tideglusib in progressive supranuclear palsy (PSP) generated prospective, 1-year longitudinal datasets of high-resolution T1-weighted three-dimensional MRI.The objective of this study was to develop a quantitative MRI disease progression measurement for clinical trials.The authors performed a fully automated quantitative MRI analysis employing atlas-based volumetry and provide sample size calculations based on data collected in 99 PSP patients assigned to placebo in these trials. Based on individual volumes of 44 brain compartments and structures at baseline and 52 weeks of follow-up, means and standard deviations of annualized percentage volume changes were used to estimate standardized effect sizes and the required sample sizes per group for future 2-armed, placebo-controlled therapeutic trials.The highest standardized effect sizes were found for midbrain, frontal lobes, and the third ventricle. Using the annualized percentage volume change of these structures to detect a 50% change in the 1-year progression (80% power, significance level 5%) required lower numbers of patients per group (third ventricle, n = 32; midbrain, n = 37; frontal lobe, n = 43) than the best clinical scale (PSP rating scale total score, n = 58). A combination of volume changes in these 3 structures reduced the number of required patients to only 20 and correlated best with the progression in the clinical scales.We propose the 1-year change in the volumes of third ventricle, midbrain, and frontal lobe as combined imaging read-out for clinical trials in PSP that require the least number of patients for detecting efficacy to reduce brain atrophy. © 2017 International Parkinson and Movement Disorder Society. |
| 536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
| 542 | _ | _ | |i 2017-04-24 |2 Crossref |u http://doi.wiley.com/10.1002/tdm_license_1 |
| 542 | _ | _ | |i 2017-04-24 |2 Crossref |u http://onlinelibrary.wiley.com/termsAndConditions |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Clinical Trials as Topic: methods |2 MeSH |
| 650 | _ | 2 | |a Disease Progression |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Frontal Lobe: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Longitudinal Studies |2 MeSH |
| 650 | _ | 2 | |a Magnetic Resonance Imaging: methods |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Mesencephalon: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Supranuclear Palsy, Progressive: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Third Ventricle: diagnostic imaging |2 MeSH |
| 700 | 1 | _ | |a Schöpe, Jakob |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Stamelou, Maria |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Kassubek, Jan |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Del Ser, Teodoro |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Boxer, Adam L |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Wagenpfeil, Stefan |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Huppertz, Hans-Jürgen |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Investigators, AL-108-231 |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Investigators, Tauros MRI |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Group, Movement Disorder Society-Endorsed PSP Study |b 10 |
| 773 | 1 | 8 | |a 10.1002/mds.26973 |b : Wiley, 2017-04-24 |n 6 |p 842-852 |3 journal-article |2 Crossref |t Movement Disorders |v 32 |y 2017 |x 0885-3185 |
| 773 | _ | _ | |a 10.1002/mds.26973 |g Vol. 32, no. 6, p. 842 - 852 |0 PERI:(DE-600)2041249-6 |n 6 |q 32:6<842 - 852 |p 842-852 |t Movement disorders |v 32 |y 2017 |x 0885-3185 |
| 856 | 7 | _ | |2 Pubmed Central |u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808453 |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:139314 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2811373 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |2 G:(DE-HGF)POF3-300 |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-11 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOVEMENT DISORD : 2021 |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-11 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-11 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOVEMENT DISORD : 2021 |d 2022-11-11 |
| 920 | 1 | _ | |0 I:(DE-2719)1110002 |k AG Höglinger 1 |l Translational Neurodegeneration |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1110002 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1007/s40263-016-0347-2 |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s40263-016-0347-2 |
| 999 | C | 5 | |a 10.1016/S1474-4422(14)70088-2 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/S1474-4422(14)70088-2 |
| 999 | C | 5 | |a 10.1002/mds.25824 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.25824 |
| 999 | C | 5 | |a 10.1002/mds.25815 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.25815 |
| 999 | C | 5 | |a 10.1002/mds.26580 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.26580 |
| 999 | C | 5 | |a 10.1016/j.parkreldis.2016.04.006 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.parkreldis.2016.04.006 |
| 999 | C | 5 | |a 10.1093/brain/awm032 |9 -- missing cx lookup -- |2 Crossref |o 10.1093/brain/awm032 |
| 999 | C | 5 | |a 10.1212/WNL.0000000000003305 |9 -- missing cx lookup -- |2 Crossref |o 10.1212/WNL.0000000000003305 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2009.10.066 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2009.10.066 |
| 999 | C | 5 | |a 10.1016/j.mri.2015.12.031 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.mri.2015.12.031 |
| 999 | C | 5 | |a 10.1002/mds.26715 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.26715 |
| 999 | C | 5 | |a 10.1212/WNL.47.1.1 |9 -- missing cx lookup -- |2 Crossref |o 10.1212/WNL.47.1.1 |
| 999 | C | 5 | |y 1997 |2 Crossref |o Golbe 1997 |
| 999 | C | 5 | |y 1969 |2 Crossref |t Third Symposium on Surgery in Parkinson's Disease |o Schwab Third Symposium on Surgery in Parkinson's Disease 1969 |
| 999 | C | 5 | |2 Crossref |o |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2007.07.007 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2007.07.007 |
| 999 | C | 5 | |a 10.1176/appi.ajp.162.7.1256 |9 -- missing cx lookup -- |2 Crossref |o 10.1176/appi.ajp.162.7.1256 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2006.01.021 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2006.01.021 |
| 999 | C | 5 | |a 10.1016/j.schres.2005.11.020 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.schres.2005.11.020 |
| 999 | C | 5 | |a 10.1016/j.biopsych.2006.06.027 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.biopsych.2006.06.027 |
| 999 | C | 5 | |a 10.1002/hbm.10123 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/hbm.10123 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2007.09.031 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2007.09.031 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2014.09.034 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2014.09.034 |
| 999 | C | 5 | |a 10.1212/01.WNL.0000165960.04422.D0 |9 -- missing cx lookup -- |2 Crossref |o 10.1212/01.WNL.0000165960.04422.D0 |
| 999 | C | 5 | |a 10.1002/mds.26921 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.26921 |
| 999 | C | 5 | |y 2001 |2 Crossref |o Whitwell 2001 |
| 999 | C | 5 | |y 1979 |2 Crossref |o Holm 1979 |
| 999 | C | 5 | |y 2006 |2 Crossref |t Nonparametrics: Statistical Methods Based on Ranks |o Lehmann Nonparametrics: Statistical Methods Based on Ranks 2006 |
| 999 | C | 5 | |a 10.1007/s00415-006-0396-4 |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s00415-006-0396-4 |
| 999 | C | 5 | |a 10.1016/j.parkreldis.2011.10.013 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.parkreldis.2011.10.013 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2015.07.087 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2015.07.087 |
| 999 | C | 5 | |a 10.1136/jnnp-2014-309768 |9 -- missing cx lookup -- |2 Crossref |o 10.1136/jnnp-2014-309768 |
| 999 | C | 5 | |a 10.1002/mds.23912 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.23912 |
| 999 | C | 5 | |a 10.1007/s00234-009-0645-1 |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s00234-009-0645-1 |
| 999 | C | 5 | |a 10.1016/S1474-4422(11)70263-0 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/S1474-4422(11)70263-0 |
| 999 | C | 5 | |y 2014 |2 Crossref |o Jones 2014 |
| 999 | C | 5 | |2 Crossref |o Höglinger |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2010.01.061 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2010.01.061 |
| 999 | C | 5 | |a 10.1016/j.neurobiolaging.2013.04.006 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neurobiolaging.2013.04.006 |
| 999 | C | 5 | |a 10.1007/s00415-016-8374-y |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s00415-016-8374-y |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|